Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

Abstract:
A needle-free vaccine platform that elicits a robust immune response against a wide array of viruses and bacteria has been awarded a U.S. patent. The University of Michigan holds the patent and NanoBio Corporation, a spin-off from the university, licenses the patent and its associated technology.

New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

ANN ARBOR, MI | Posted on January 30th, 2008

The intranasal vaccines, produced using NanoBio's nanoemulsion technology, have elicited a dramatic immune response in animals vaccinated against influenza, anthrax, hepatitis B and other diseases. In some cases, the immune response is exponentially higher than what is required to provide adequate protection against infection. Such dramatic levels of immunity would confer significantly higher levels of protection to the vaccinated population at large compared with current injectable vaccines.

Because the vaccines trigger such robust immunity, scientists anticipate they will be able to reduce vaccine antigen quantities to a fraction of what current vaccines require, while still mounting an overwhelming immune response.

This "antigen-sparing" capability would enable scientists to rapidly produce large quantities of vaccines using miniscule amounts of antigen, a critical factor when faced with a disease pandemic or biological warfare.

"We have shown that when we mix our nanoemulsion with whole virus or a recombinant protein antigen and apply it to the naso-pharynx, the resulting vaccine elicits strong mucosal and systemic immunity," said James R. Baker Jr., M.D., founder and Chairman of NanoBio Corporation. "The nanoemulsion serves as an adjuvant to boost immune response against a specific antigen."

NanoBio is in various stages of testing its extensive pipeline of mucosal vaccines for influenza, bird flu, hepatitis B, HIV, RSV, small pox, anthrax and other viral and bacterial infections. Final results from the influenza vaccine study in ferrets are expected this quarter, and human tests with the influenza and hepatitis B vaccines are being planned.

The newly awarded patent covers the methods and compositions of formulating nanoemulsion vaccines, a unique coupling of oil, water, and antimicrobial surfactant together with antigens from specific pathogens.

Studies in animals demonstrate these vaccines easily penetrate the mucous membrane, where dendritic cells rapidly engulf the antigen and present it to the immune system. This rapid awakening of the immune system via the intranasal route negates the need for inflammatory stimulants used in traditional vaccines, which can cause pain and swelling at the site of vaccination, said Dr. Baker.

"We present antigen in an optimal location where it can most directly access the immune system," added Baker. "As a result, there is no need to prime the immune system with immunostimulants in order to provoke its recognition of the antigens."

Moreover, the vaccine requires no harsh chemicals to attenuate the whole virus and render it harmless, because the nanoemulsion itself kills the antigen. Advantages of the nanoemulsion vaccines include:

-- nasal delivery, the entry point of most respiratory infections -- development of rapid mucosal immunity followed by systemic immunity -- antigen-sparing capability -- thermally stable, requires no refrigeration -- needle-free, easy to administer

The development of the nanoemulsion platform began in 1998 and is supported, in part, by a $6.3 million grant from the Bill and Melinda Gates Foundation to the Michigan Nanotechnology Institute for Medicine and Biological Sciences, which is led by Dr. Baker. The new patent for nanoemulsion vaccines (#7,314,624 B2) is licensed to NanoBio Corporation on an exclusive, worldwide basis. With this new patent, NanoBio now holds five U.S. patents and has filed numerous additional applications in various jurisdictions.

####

About NanoBio Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

Address:2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Superconductor could be realized in a broken Lorenz invariant theory July 7th, 2015

New technique enables magnetic patterns to be mapped in 3-D July 7th, 2015

Crystal structure and magnetism -- new insight into the fundamentals of solid state physics: HZB team decodes relationship between magnetic interactions and the distortions in crystal structure within a geometrically 'frustrated' spinel system July 7th, 2015

Down to the quantum dot: Jülich researchers develop ultrahigh-resolution 3-D microscopy technique for electric fields July 7th, 2015

Nanomedicine

New technique enables magnetic patterns to be mapped in 3-D July 7th, 2015

Miniature Technology, Large-Scale Impact: Winner of the 2015 Lindros Award for translational medicine, Kjeld Janssen is pushing the boundaries of the emerging lab-on-a-chip technology - See more at: http://www.news.ucsb.edu/2015/015744/miniature-technology-large-scale-impact#stha July 7th, 2015

A Stretchy Mesh Heater for Sore Muscles July 6th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Announcements

Superconductor could be realized in a broken Lorenz invariant theory July 7th, 2015

New technique enables magnetic patterns to be mapped in 3-D July 7th, 2015

Crystal structure and magnetism -- new insight into the fundamentals of solid state physics: HZB team decodes relationship between magnetic interactions and the distortions in crystal structure within a geometrically 'frustrated' spinel system July 7th, 2015

Down to the quantum dot: Jülich researchers develop ultrahigh-resolution 3-D microscopy technique for electric fields July 7th, 2015

Patents/IP/Tech Transfer/Licensing

GLOBALFOUNDRIES Completes Acquisition of IBM Microelectronics Business: Transaction adds differentiating technologies, world-class technologists, and intellectual property July 1st, 2015

NEI Announces the Issuance of Multiple Patents on Self-Healing & Superhydrophobic Coatings June 30th, 2015

Solegear Further Strengthens its Product Development Team: New Hire Seeks to Create New, Disruptive, Sustainable Materials June 17th, 2015

High-tech nanofibres could help nutrients in food hit the spot June 17th, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Miniature Technology, Large-Scale Impact: Winner of the 2015 Lindros Award for translational medicine, Kjeld Janssen is pushing the boundaries of the emerging lab-on-a-chip technology - See more at: http://www.news.ucsb.edu/2015/015744/miniature-technology-large-scale-impact#stha July 7th, 2015

Pioneering Southampton scientist awarded prestigious physics medal July 3rd, 2015

Discovery of nanotubes offers new clues about cell-to-cell communication July 2nd, 2015

World’s 1st Full-Color, Flexible, Skin-Like Display Developed at UCF June 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project